CONCLUSION

- Overall, similar percentages of participants reported any TEA among patients treated with hydroxyurea (1500 mg; 84.2%, hydroxyurea 1800 mg; 84.4%, placebo 900 mg, 96.6%, placebo 97.1%).
- Percentages of participants reporting any serious TEA were also similar among specific laboratory parameters including MCV: placebo 1500 mg, 52.6%, hydroxyurea 1500 mg, 54.2%, placebo 900 mg, 48.1%, and without hydroxyurea (1500 mg, 45.2%, placebo 900 mg, 48.4%, placebo 52.5%).

ACKNOWLEDGEMENTS

- We thank all the patients with sickle cell disease, families, caregivers, research nurses, study coordinators, and support staff who contributed to this study.

REFERENCES


DISCLAIMERS

- Russell Ware: Bristol-Myers Squibb, AbbVie, Biomedocs, Biomedical, research support; Global Blood Therapeutics, Agios, Novo Nordisk, Novartis, FDA, consultant. Clark Brown: Global Blood Therapeutics, trial investigator; Novartis, Pfizer, research support; Global Blood Therapeutics, Imara, consultant. Marianne de Montalembert: Amedica, Novartis, levels bio, co-investigator; Margaret Tonda, Barbara Tong: Global Blood Therapeutics, employees and stockholders. Carolyn Hoppe: Boehringer, Imara, Novartis, consultant or advisor; General Blood Therapeutics, employee and stockholder. Joshua Leifer-Grauer: Global Blood Therapeutics, former employee and former stockholder. Miguel R. Abboud: Novartis, Novo Nordisk, consultant; Global Blood Therapeutics, Lilly, Modus Pharmacuticals, research funding.
- Lisa Chu, Pharrma Healthcare Consulting Group, Inc. with funding from Global Blood Therapeutics provided editorial assistance in the preparation of this report.
- This study was sponsored by Global Blood Therapeutics.